Core Viewpoint - Pfizer, as a leading pharmaceutical company, is generating substantial cash flow, primarily driven by its innovative medicines and COVID-19 products, allowing it to return significant value to shareholders through dividends and potential future increases in payouts [1][2]. Group 1: Dividend Payments - Pfizer announced a dividend increase to $0.42 per share, up from $0.41, indicating a commitment to returning value to shareholders [2]. - The company is expected to distribute approximately $9.52 billion in dividends this year, based on its outstanding shares of about 5.67 billion [2]. Group 2: Share Repurchase and Stock Performance - Pfizer's existing share repurchase authorization is $3.3 billion; however, the company does not plan to repurchase shares this year, which may impact the stock's performance [2]. - The stock currently offers a yield of 5.8%, making it attractive for investors seeking income [3]. Group 3: Revenue and Growth Potential - Despite a decline in total sales, excluding COVID-19 products and currency fluctuations, Pfizer's first-quarter revenue increased by 11% year over year, indicating underlying growth potential [3]. - With the worst impacts of COVID-19 behind, Pfizer's profitability is expected to improve significantly over the coming years, making it a favorable addition to diversified investment portfolios [3].

Going against the grain here looks like a great idea.When looking to invest in dividend stocks, chasing high yields isn't always an advisable strategy. Companies with juicy yields are only worth investing in provided they can support their payouts. We saw just recently that even otherwise solid income stocks with incredible yields can resort to slashing their dividends; that's exactly what happened to Walgreens Boots Alliance and Medical Properties Trust.Not every high-yield stock will suffer this fate, tho ...

These are three solid contenders for your portfolio.It's hard to beat stocks when you're looking to build wealth over many years. Per the research of Wharton professor Jeremy Siegel, stocks have outperformed bonds, gold, and the dollar over more than 200 years.Bonds were the closest competitor, but stocks beat bonds over relatively shorter periods, too; over the 75 years between 1946 and 2021, stocks grew at an average annual rate of 11.3%, versus 5.8% for long-term government bonds. (The long-term annual a ...

Pfizer (PFE) announced that it is launching a new cost-restructuring program to reduce its spending. Spanning across multiple years, the program intends to reduce the company’s costs of goods sold in a multi-phased effort.The first phase of the program, which is focused on operational efficiencies, is expected to save nearly $1.5 billion by the end of 2027. Management expects to start realizing these savings next year.Pfizer expects to incur about $1.7 billion as one-time costs for the first phase of the pr ...

From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 200-day moving average, and this suggests a long-term bullish trend.The 200-day simple moving average is widely-used by traders and analysts, and helps establish market trends for stocks, commodities, indexes, and other financial instruments over the long term. The indicator moves higher or lower together with longer-term price moves, serving as a support or re ...

Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City.Pfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition to another $4 billion cost-cutting effort, which Pfizer announced last year as demand for its Covid vaccine and oral drug Paxlovid slumped. In a securities filing, the pharmaceutical giant said the first phase of its new program is focused on ...

Pfizer stock lost nearly half its value over the past couple of years, but some of the world's most successful investors bought millions of shares in the first quarter.The past couple of years haven't been easy ones to be a Pfizer (PFE -0.38%) shareholder. The windfall profits its COVID-19 products produced in the early days of the pandemic evaporated much faster than expected.Disappointed investors have pushed Pfizer's stock price down by more than half from its peak in late 2021. Perhaps sensing a bargain ...

More than a dozen S&P 500 components sport "ultra-high yields." Two of these time-tested titans are begging to be bought by income seekers right now.Stocks have been a wealth-creating machine for investors over the long run. Though other asset classes have delivered a positive nominal return to patient investors, including gold, oil, housing, and Treasury bonds, none have come close to the annualized total return stocks have generated over the last century.While innovation is a key growth driver on Wall Str ...

Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.Are you famous enough for picking great stocks to become a billionaire money manager? If not, then there's a lot you could learn from the handful of folks who have.It's easier than ever for individuals to invest alongside the professionals. The U.S. Securities and Exchange Commission makes anyone with more than $100 million under management report their activity to the public every three months. T ...

JHVEPhoto Overview Pfizer (NYSE:PFE) (NEOE:PFE:CA) has struggled to gain any sort of recovery momentum since it suffered losses in revenue coming off the tail end of the pandemic. In addition, the upcoming patent expiries seem to be a source of concern for many investors here as we try to figure out how PFE will whether that storm. I previously covered PFE back in January and rated it a Strong Buy, and the total return since then has been mostly flat. Data by YCharts I wanted to take this opportunity to ...